1. A vaccine composition for administration to the oral cavity of a human or animal, the vaccine composition comprising: at least one antigen isolated from an object with an infectious disease, and at least one agent selected from the group consisting of: toll-like receptor agonist 4 (TLR4), a toll-like receptor agonist 2/6 (TLR2 / 6) of acyclic dinucleotide or a derivative or salt thereof. 2. The vaccine composition according to claim 1, wherein the antigen isolated from an object with an infectious disease is an antigen isolated from an influenza virus. The vaccine composition of claim 2, wherein the antigen isolated from the influenza virus is a hemagglutinin protein. The vaccine composition of claim 2, wherein the antigen isolated from the influenza virus is an inactivated whole virus. The vaccine composition according to claim 1, wherein the toll-like receptor 4 (TLR4) agonist comprises at least one agent selected from the group consisting of: a lipopolysaccharide or a salt thereof, an monophosphoryl lipid or a salt thereof. The vaccine composition of claim 5, wherein the lipopolysaccharide or its salt is isolated from Escherichia coli, Salmonella, Pantoea, Acetobacterium, Zymomonas, Xanthomonas or Enterobacter； the monophosphoryl lipid or its salt is a monophosphoryl lipid isolated from Salmonella or a synthetic glucopyranosyl lipid. 7. The vaccine composition of claim 1, wherein the toll-like receptor agonist 2/6 (TLR2 / 6) comprises a diacylated lipopeptide or a derivative or salt thereof. The vaccine composition of claim 7, wherein the diacylated lipopeptide comprises PamCSK, MALP-2, FSL-1 or derivatives or salts thereof. The vaccine composition of claim 1, wherein the cyclic dinucleotide comprises c-di-GMP, c-di-AMP, or derivatives or salts thereof. The vaccine composition according to claim 6, where1. Вакцинная композиция для введения в ротовую полость человека или животного, причем вакцинная композиция включает:по меньшей мере один антиген, выделенный из
